NO20064274L - 8-hydroksy-5-[(-hydroksy-2[[ (1R)-2-(4-metoksyfenyl)-1-metylyletyl] amino][etyl]-2(1H)-quinolinon monohydroklond i krystallinsk form og fremgangsmaten for dens fremstilling - Google Patents

8-hydroksy-5-[(-hydroksy-2[[ (1R)-2-(4-metoksyfenyl)-1-metylyletyl] amino][etyl]-2(1H)-quinolinon monohydroklond i krystallinsk form og fremgangsmaten for dens fremstilling

Info

Publication number
NO20064274L
NO20064274L NO20064274A NO20064274A NO20064274L NO 20064274 L NO20064274 L NO 20064274L NO 20064274 A NO20064274 A NO 20064274A NO 20064274 A NO20064274 A NO 20064274A NO 20064274 L NO20064274 L NO 20064274L
Authority
NO
Norway
Prior art keywords
hydroxy
methoxyphenyl
ethyl
amino
crystalline form
Prior art date
Application number
NO20064274A
Other languages
English (en)
Norwegian (no)
Inventor
Roberto Pighi
Fausto Pivetti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064274(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of NO20064274L publication Critical patent/NO20064274L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20064274A 2004-03-24 2006-09-21 8-hydroksy-5-[(-hydroksy-2[[ (1R)-2-(4-metoksyfenyl)-1-metylyletyl] amino][etyl]-2(1H)-quinolinon monohydroklond i krystallinsk form og fremgangsmaten for dens fremstilling NO20064274L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04007045 2004-03-24
PCT/EP2005/003144 WO2005089760A1 (en) 2004-03-24 2005-03-24 8-hydroxy-5-[(-hydroxy-2-[[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl] -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation

Publications (1)

Publication Number Publication Date
NO20064274L true NO20064274L (no) 2006-10-13

Family

ID=34963779

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064274A NO20064274L (no) 2004-03-24 2006-09-21 8-hydroksy-5-[(-hydroksy-2[[ (1R)-2-(4-metoksyfenyl)-1-metylyletyl] amino][etyl]-2(1H)-quinolinon monohydroklond i krystallinsk form og fremgangsmaten for dens fremstilling

Country Status (30)

Country Link
US (1) US20070197586A1 (zh)
EP (1) EP1729773B1 (zh)
JP (1) JP2007530489A (zh)
KR (1) KR20070001946A (zh)
CN (2) CN1929840B (zh)
AR (1) AR048339A1 (zh)
AT (1) ATE399552T1 (zh)
AU (1) AU2005224032A1 (zh)
BR (1) BRPI0508213A (zh)
CA (1) CA2560650A1 (zh)
CY (1) CY1108323T1 (zh)
DE (1) DE602005007871D1 (zh)
DK (1) DK1729773T3 (zh)
EA (1) EA010128B1 (zh)
ES (1) ES2309739T3 (zh)
HR (1) HRP20080495T3 (zh)
IL (1) IL178227A0 (zh)
MA (1) MA28549B1 (zh)
MX (1) MXPA06010515A (zh)
NO (1) NO20064274L (zh)
NZ (1) NZ550010A (zh)
PE (1) PE20060159A1 (zh)
PL (1) PL1729773T3 (zh)
PT (1) PT1729773E (zh)
RS (1) RS50602B (zh)
SI (1) SI1729773T1 (zh)
TN (1) TNSN06249A1 (zh)
UA (1) UA86221C2 (zh)
WO (1) WO2005089760A1 (zh)
ZA (1) ZA200607907B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride
EP2116537A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
EP2360147A1 (en) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB9603237D0 (en) * 1996-02-16 1996-04-17 Sandoz Ltd Organic compounds
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
CA2534693A1 (en) * 2003-08-05 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and a betamimetic
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride
EP2116537A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride

Also Published As

Publication number Publication date
SI1729773T1 (sl) 2008-10-31
ZA200607907B (en) 2008-04-30
AU2005224032A1 (en) 2005-09-29
MA28549B1 (fr) 2007-04-03
UA86221C2 (en) 2009-04-10
EP1729773A1 (en) 2006-12-13
CA2560650A1 (en) 2005-09-29
CN1929840A (zh) 2007-03-14
BRPI0508213A (pt) 2007-07-17
PE20060159A1 (es) 2006-04-04
TNSN06249A1 (en) 2007-12-03
MXPA06010515A (es) 2007-03-30
RS50602B (sr) 2010-05-07
EA010128B1 (ru) 2008-06-30
DE602005007871D1 (de) 2008-08-14
ATE399552T1 (de) 2008-07-15
US20070197586A1 (en) 2007-08-23
AR048339A1 (es) 2006-04-19
WO2005089760A1 (en) 2005-09-29
EA200601531A1 (ru) 2007-04-27
CN1929840B (zh) 2010-12-08
CN101812017A (zh) 2010-08-25
HRP20080495T3 (en) 2008-11-30
CY1108323T1 (el) 2014-02-12
PT1729773E (pt) 2008-09-29
EP1729773B1 (en) 2008-07-02
PL1729773T3 (pl) 2008-12-31
IL178227A0 (en) 2006-12-31
KR20070001946A (ko) 2007-01-04
JP2007530489A (ja) 2007-11-01
ES2309739T3 (es) 2008-12-16
DK1729773T3 (da) 2008-10-20
NZ550010A (en) 2010-08-27

Similar Documents

Publication Publication Date Title
US8633219B2 (en) Combination therapy
LU92602I2 (fr) Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
FI4159217T3 (fi) Mek-estäjän ja b-raf-estäjän käsittävä yhdistelmä
RS20050615A (en) Medicamentt comprising a highly long-lasting beta2-agonist in combination with other active ingredients
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
WO2009049180A3 (en) Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
WO2006011050A3 (en) Pyridine derivatives
WO2007041130A3 (en) Deazapurines useful as inhibitors of janus kinases
WO2007120647A3 (en) Compositions useful as inhibitors of voltage-gated sodium channels
IL176416A (en) History of Nitroxy prostaglandin, pharmaceutical preparations containing them, and their use in the preparation of the drug for the treatment of glaucoma or intraocular pressure
JP2008504266A5 (zh)
WO2007014940A8 (en) Quinoline derivatives as antibacterical agents
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
EP2650293A8 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
NO20064274L (no) 8-hydroksy-5-[(-hydroksy-2[[ (1R)-2-(4-metoksyfenyl)-1-metylyletyl] amino][etyl]-2(1H)-quinolinon monohydroklond i krystallinsk form og fremgangsmaten for dens fremstilling
WO2002102793A3 (en) Quinazolinediones as antibacterial agents
WO2008010238A3 (en) Antidiabetic azabicyclo [3. 1. 0] hexan compounds
WO2004094386A8 (en) Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b)
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
WO2007126900A3 (en) Antifungal agents
WO2005090287A3 (en) Phenylethanolamine derivatives as beta-2 agonists
WO2006103545A8 (en) 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
AR054888A1 (es) Derivados de quinolina como agentes antibacterianos
EA200800154A1 (ru) Производные хинолина в качестве антибактериальных средств

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application